{"id":6844,"date":"2018-12-13T23:49:40","date_gmt":"2018-12-13T22:49:40","guid":{"rendered":"https:\/\/www.richter.ca\/insolvencycase\/aralez-pharmaceuticals-2\/"},"modified":"2019-05-31T16:22:41","modified_gmt":"2019-05-31T14:22:41","slug":"aralez-pharmaceuticals","status":"publish","type":"insolvencies","link":"https:\/\/www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/","title":{"rendered":"Aralez Pharmaceuticals"},"content":{"rendered":"<section class=\"result-doc\">\n<ul class=\"collapsible\">\n<li class=\"collapse\"><span class=\"gen-enclosed foundicon-plus\">Proc\u00e9dures relatives \u00e0 la LACC<\/span>\n<ul class=\"collapsible\">\n<li style=\"list-style-type: none\">\n<ul class=\"collapsible\">\n<li class=\"collapse\"><a href=\"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/12\/083-monitors-certificate.pdf\">Certificat de contr\u00f4leur &#8211; dat\u00e9 30 mai 2019<\/a><\/li>\n<\/ul>\n<\/li>\n<li class=\"collapse\"><span class=\"gen-enclosed foundicon-plus\">Proc\u00e9dure de r\u00e9clamations<\/span>\n<ul class=\"collapsible\">\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Claims-Procedure\/Notice-Letter-20181010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Avis aux r\u00e9clamants pour la proc\u00e9dure de r\u00e9clamation (version anglaise seulement) &#8211; dat\u00e9 10 octobre 2018 &#8211; 63 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Claims-Procedure\/POC.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Preuve de r\u00e9clamation &#8211; 173 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Claims-Procedure\/Instruction-Letter-20181010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Lettre d&rsquo;instruction &#8211; dat\u00e9 10 octobre 2018 &#8211; 88 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Claims-Procedure\/Claims-Procedure-Order-20181010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ordonnance de proc\u00e9dure de r\u00e9clamation (version anglaise seulement) &#8211; dat\u00e9 10 octobre 2018 &#8211; 5 mo<\/a><\/li>\n<\/ul>\n<\/li>\n<li class=\"collapse\"><span class=\"gen-enclosed foundicon-plus\">Ordonnances de la cour<\/span>\n<ul>\n<li><a href=\"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/12\/061-aralez-pharmaceutics-inc-re-keip-approval-order.pdf\">Ordonnance (Re:\u00a0KEIP Approbation)\u00a0&#8211;\u00a0dat\u00e9\u00a028\u00a0novembre\u00a02018<\/a><\/li>\n<li class=\"collapse\"><a href=\"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/12\/060-re-aralez-pharmaceuticals-inc--et-al--distribution-order-dec--17-2018.pdf\">Ordonnance de distribution &#8211; (version anglaise seulement) &#8211; dat\u00e9 17 d\u00e9cembre 2018<\/a><\/li>\n<li class=\"collapse\"><a href=\"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/12\/059-aralez-pharmaceuticals-inc--et-al--unofficial-typed-version-of-dunphy-j-s-endorsement-dec--17.pdf\">\u00a0Version dactylographi\u00e9e non officielle de l&rsquo;endossement du juge Dunphy (version anglaise) &#8211; dat\u00e9 17 d\u00e9cembre <\/a><\/li>\n<li class=\"collapse\"><a href=\"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/12\/058-aralez-pharmaceuticals-inc--et-al--endorsement-of-dunphy-j--dec--17-2018.pdf\">Endossement\u00a0 &#8211; (version anglaise seulement) &#8211; dat\u00e9 17 d\u00e9cembre 2018<\/a><\/li>\n<li class=\"collapse\"><a href=\"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/12\/057-aralez-pharmaceuticals-inc--et-al--bezafibrate-order-dec--17-2018.pdf\">Bezafibrate Ordonnance\u00a0 &#8211; (version anglaise seulement) &#8211; dat\u00e9 17 d\u00e9cembre 2018<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/49-Termination-order-20181210.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Aralez Canada LACC- Ordonnance de r\u00e9siliation en vertu de la LACC &#8211; (version anglaise) &#8211; dat\u00e9 10 d\u00e9cembre 2018 &#8211; 164 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/50-Handwritten-endorsement-20181210.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Endossement (version anglaise seulement) &#8211; dat\u00e9 10 d\u00e9cembre 2018 &#8211; 30 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/51-Unofficial-Typed-Vesion-of-endorsement-20181210.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Version dactylographi\u00e9e non officielle de l&rsquo;endossement du juge Dunphy &#8211; (version anglaise seulement) &#8211; dat\u00e9e du 10 d\u00e9cembre 2018 -80 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/48-Approval-and-vesting-order-20181210.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Approbation et ordre d&rsquo;acquisition &#8211; (version anglaise seulement) &#8211; dat\u00e9 10 d\u00e9cembre 2018 &#8211; 219 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/47-Stay-extension-order-20181210.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ordonnance prolongeant la p\u00e9riode de d\u00e9p\u00f4t (version anglaise seulement) &#8211; dat\u00e9 10 d\u00e9cembre 2018 &#8211; 53 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/42-Unofficial-typed-version-20181121.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Version dactylographi\u00e9e non officielle d&rsquo;endossement de l&rsquo;honorable Dunphy J. &#8211; (version anglaise seulement) &#8211; dat\u00e9 du 21 novembre 2018 98 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/41-OrderKERP-Approval.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ordonnance (Re: KERP approbation) &#8211; (Version anglaise seulement) &#8211; dat\u00e9 21 novembre 2018 &#8211; 519 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/40--hand-written-endorsement-20181121.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Endossement \u00e9crit \u00e0 la main- (Re: KERP) &#8211; (version anglaise seulement) &#8211; dated November 21, 2018 &#8211; 68 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Unofficial-transcript-endorsement-20181025.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Traduction dactylographi\u00e9e non officielle de l&rsquo;endossement (version anglaise seulement) &#8211; dat\u00e9 25 octobre 2018 &#8211; 74 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/25-Order-KEIP.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Raisons pour decision (Re: KEIP) &#8211; (version anglaise seulement) &#8211; dated November 21, 2018 &#8211; 3 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Endorsement-Cross-Border-Protocol-20181025.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Endossement (version anglaise seulement) &#8211; dat\u00e9 25 octobre 2018 &#8211; 40 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Order-Cross-Border-Protocol-20181025.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ordonnance (protocole) (version anglaise seulement) &#8211; dat\u00e9 25 octobre 2018 &#8211; 1 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Endorsement-20181010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Endossement (version anglaise seulement) &#8211; dat\u00e9 10 octobre 2018 &#8211; 1 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Unofficial-transcript-of-endorsement-20181010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Traduction dactylographi\u00e9e non officielle de l&rsquo;endossement (version anglaise seulement) &#8211; dat\u00e9 10 octobre 2018 &#8211; 83 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Bidding-Procedures-Order-20181010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ordonnance (Approbation proc\u00e9dures d&rsquo;appel d&rsquo;offres) (version anglaise seulement) &#8211; dat\u00e9 10 octobre 2018 &#8211; 382 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Stay-Extension-Order-20181010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ordonnance prolongeant la p\u00e9riode de d\u00e9p\u00f4t au 7 d\u00e9cembre 2018 (version anglaise seulement) &#8211; dat\u00e9 10 octobre 2018 &#8211; 515 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Endorsement-20180905.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Endossement (version anglaise seulement) &#8211; dat\u00e9 5 septembre 2018 &#8211; 64 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Stay-Extension-Order-20180905.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ordonnance prolongeant la p\u00e9riode de d\u00e9p\u00f4t au 14 novembre 2018 (version anglaise seulement) &#8211; dat\u00e9 5 septembre 2018 &#8211; 47 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Amended-Restated-Order-20180810.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ordonnance initiale amend\u00e9e et reformul\u00e9e (version anglaise seulement) &#8211; dat\u00e9 5 septembre 2018 &#8211; 244 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Court-orders\/Order-20180810.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ordonnance initiale (version anglaise seulement) &#8211; dat\u00e9 10 ao\u00fbt 2018 &#8211; 5 mo<\/a><\/li>\n<\/ul>\n<\/li>\n<li class=\"collapse\"><span class=\"gen-enclosed foundicon-plus\">Convention de cr\u00e9dit de d\u00e9biteur<\/span>\n<ul class=\"collapsible\">\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/DIP-Credit-Agreement\/Affidavit-Kathryn-Esaw-20180810.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Affidavit de Kathryn Esaw &#8211; Asserment\u00e9 le 10 ao\u00fbt 2018 (version anglaise seulement) &#8211; 4 mo<\/a><\/li>\n<\/ul>\n<\/li>\n<li class=\"collapse\"><span class=\"gen-enclosed foundicon-plus\">Formulaires<\/span>\n<ul class=\"collapsible\">\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Forms\/Form-1-20180810.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Formulaire 1 &#8211; Renseignements concernant l&rsquo;Ordonnance initiale (version anglaise seulement) &#8211; dat\u00e9 10 ao\u00fbt 2018 &#8211; 70 ko<\/a><\/li>\n<\/ul>\n<\/li>\n<li class=\"collapse\"><span class=\"gen-enclosed foundicon-plus\">Requ\u00eates<\/span>\n<ul class=\"collapsible\">\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/56-Book-of-authorities-20181213.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Liste des sources des applicants (pr\u00e9sentable 17 d\u00e9cembre 2018) &#8211; (objet: approbation de vente Bezafibrate) &#8211; (version anglaise seulement) &#8211; dat\u00e9 13 d\u00e9cembre 2018 &#8211; 996 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/55-Factum-of-the-applicants-20181213.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">M\u00e9moire du demandeur (pr\u00e9sentable 17 d\u00e9cembre 2018) &#8211; (approbation de la vente Bezafibrate) &#8211; (version anglaise seulement) &#8211; dat\u00e9 13 d\u00e9cembre 2018 &#8211; 177 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/54-Notice-of-Motion-dist-order.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Requ\u00eate des demandeurs (pr\u00e9sentable 17 d\u00e9cembre 2018) -(objet: ordonnance de distribution) &#8211; (version anglaise seulement) &#8211; dat\u00e9 12 d\u00e9cembre 2018 &#8211; 6 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/45-Motion-record-bezafibrate-20181206.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Requ\u00eate des demandeurs (pr\u00e9sentable 17 decembre 2018) &#8211; ( Objet: approbation de la vente Bezafibrate) (version anglaise seulement) &#8211; dat\u00e9 6 d\u00e9cembre 2018 &#8211; 4 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/46-Solicitors-Affidavit-S-Dukesz-20181206.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Affidavit de Shimshon Dukesz (Asserment\u00e9 le 6 d\u00e9cembre 2018) (version anglaise seulement) \u2013507 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/44-factum-of-applicants-20181205.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">M\u00e9moire du demandeur (pr\u00e9sentable 7 d\u00e9cembre 2018) (version anglaise seulement) &#8211; dat\u00e9 5 d\u00e9cembre 2018 &#8211; 215 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Motion-20181130.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Requ\u00eate des demandeurs (pr\u00e9sentable 7 decembre 2018) &#8211; (version anglaise seulement) &#8211; dat\u00e9 30 novembre 2018 &#8211; 35 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/36-Factum-of-the-applicants-20181114.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">M\u00e9moire du demandeur (pr\u00e9sentable 16 novembre 2018) (version anglaise seulement) &#8211; dat\u00e9 14 novembre 2018 &#8211; 208 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/34-Factum-official-commitee-20181115.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">M\u00e9moire du comit\u00e9 officiel des cr\u00e9anciers non garantis &#8211; (pr\u00e9sentable 16 novembre 2018) (version anglaise seulement) &#8211; dat\u00e9 14 novermbre 2018 &#8211; 330 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/35-book-of-authorities.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Liste des sources (pr\u00e9sentable 16 novenbre 2018) (version anglaise seulement) &#8211; dat\u00e9 14 novembre 2018 &#8211; 4 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/32-motion-record-20181108.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Requ\u00eate des demandeurs (pr\u00e9sentable 16 novembre 2018) (re: approbation KERP and KEIP) (version anglaise seulement) &#8211; dat\u00e9 8 novembre 2018 &#8211; 1 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Factum-Cross-Border-Protocol-20181023.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">M\u00e9moire du demandeur (pr\u00e9sentable 25 octobre 2018) (version anglaise seulement) &#8211; dat\u00e9 23 octobre 2018 &#8211; 134 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Book-of-authorities-Cross-broder-motion-20181023.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Liste des sources (Approbation du protocole) (pr\u00e9sentable 25 octobre 2018) (version anglaise seulement) &#8211; dat\u00e9 23 octobre 2018 &#8211; 490 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Cross-Border-Protocol-Motion-20191019.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Requ\u00eate (Approbation du protocole) (pr\u00e9sentable 25 octobre 2018) (version anglaise seulement) &#8211; dat\u00e9 19 octobre 2018 &#8211; 2 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Affidavit-KEsaw-20181010.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Affidavit de Kathryn Esaw (asserment\u00e9 10 octobre 2018) (version anglaise seulement) &#8211; dat\u00e9 10 octobre 2018 &#8211; 14 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Factum-20181005.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">M\u00e9moire du demandeur (pr\u00e9sentable 10 octobre 2018) (version anglaise seulement) &#8211; dat\u00e9 5 octobre 2018 &#8211; 387 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Motion-Record-20181001.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Requ\u00eate des demandeurs (pr\u00e9sentable 10 octobre 2018) (re: proc\u00e9dure d&rsquo;appel d&rsquo;offres, proc\u00e9dure de r\u00e9clamation et p\u00e9riode de d\u00e9lai) (version anglaise seulement) &#8211; dat\u00e9 1er octobre 2018 &#8211; 87 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Factum-20180904.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">M\u00e9moire du demandeur (pr\u00e9sentable 5 septembre 2018) (version anglaise seulement) &#8211; dat\u00e9 4 septembre 2018 &#8211; 266 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Motion-Record-20180828.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Requ\u00eate (Prolongation de d\u00e9lai, frais de transaction, protocole transfrontalier) (pr\u00e9sentable 5 septembre 2018) (version anglaise seulement) &#8211; dat\u00e9 28 ao\u00fbt 2018 &#8211; 7 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Application-Record-20180809.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Requ\u00eate (pr\u00e9sentable 10 ao\u00fbt 2018) (version anglaise seulement) &#8211; dat\u00e9 9 ao\u00fbt 2018 &#8211; 25 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Motion-materials\/Brief-of-law-20180809.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">M\u00e9moire des demandeurs (pr\u00e9sentable 10 ao\u00fbt 2018) (version anglaise seulement) &#8211; dat\u00e9 9 ao\u00fbt 2018 &#8211; 668 ko<\/a><\/li>\n<\/ul>\n<\/li>\n<li class=\"collapse\"><span class=\"gen-enclosed foundicon-plus\">Avis<\/span>\n<ul class=\"collapsible\">\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Notices\/Creditor-Listing-20180817.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Liste des cr\u00e9anciers (version anglaise seulement) &#8211; dated August 17, 2018 &#8211; 57 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Notices\/Notice-Initial-Order-20180817.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Avis aux cr\u00e9anciers de l&rsquo;Ordonnance initiale (version anglaise seulement) &#8211; dat\u00e9 17 ao\u00fbt 2018 &#8211; 18 ko<\/a><\/li>\n<\/ul>\n<\/li>\n<li class=\"collapse\"><span class=\"gen-enclosed foundicon-plus\">Autres<\/span>\n<ul class=\"collapsible\">\n<li><a href=\"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/12\/038-aralez-e-service_list_emails_nov-1918.pdf\">Liste de signification par courriel (version anglaise seulement) &#8211; dat\u00e9 19\u00a0 novembre 2018<\/a><\/li>\n<li><a href=\"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/12\/037-aralez-_service_list-update-nov-19_18.pdf\">Liste de signification (version anglaise seulement) &#8211; dat\u00e9 19 novembre 2018<\/a><\/li>\n<li class=\"file\"><\/li>\n<\/ul>\n<\/li>\n<li class=\"collapse\"><span class=\"gen-enclosed foundicon-plus\">Rapports<\/span>\n<ul class=\"collapsible\">\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Reports\/6th-report-of-the-Monitor-20181212.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Sixi\u00e8me rapport du Contr\u00f4leur (version anglaise seulement) &#8211; dat\u00e9 12 d\u00e9cembre 2018 &#8211; 282 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Reports\/5th-report-of-the-Monitor.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Cinqui\u00e8me rapport du Contr\u00f4leur (version anglaise seulement) &#8211; dat\u00e9 4 d\u00e9cembre 2018 &#8211; 4 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Reports\/4th-report.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Quatri\u00e8me rapport rapport du Contr\u00f4leur (version anglaise seulement) &#8211; dat\u00e9 14 novembre 2018 &#8211; 745 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Reports\/3rd-Report-of-the-Monitor-20181023.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Troisi\u00e8me rapport du Contr\u00f4leur (version anglaise seulement) &#8211; dat\u00e9 23 octobre 2018 &#8211; 296 ko<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Reports\/2nd-Report-of-the-Monitor-20181005.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Deuxi\u00e9me rapport du Contr\u00f4leur (version anglaise seulement) &#8211; dat\u00e9 5 octobre 2018 &#8211; 2 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Reports\/First-Report-of-the-Monitor---20180831.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Premier rapport du Contr\u00f4leur (version anglaise seulement) &#8211; dat\u00e9 30 ao\u00fbt 2018 &#8211; 1 mo<\/a><\/li>\n<li class=\"file\"><a href=\"https:\/\/www.richter.ca\/wp-content\/uploads\/Insolvency-Cases\/fr\/A\/Aralez-Pharmaceuticals\/CCAA-Proceedings\/Reports\/Report-of-the-proposed-monitor-20180810.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Rapport de Richter Groupe Conseil Inc., en qualit\u00e9 de Contr\u00f4leur (version anglaise seulement) &#8211; dat\u00e9 10 ao\u00fbt 2018 &#8211; 1 mo<\/a><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Proc\u00e9dures relatives \u00e0 la LACC Certificat de contr\u00f4leur &#8211; dat\u00e9 30 mai 2019 Proc\u00e9dure de r\u00e9clamations Avis aux r\u00e9clamants pour la proc\u00e9dure de r\u00e9clamation (version anglaise seulement) &#8211; dat\u00e9 10 octobre 2018 &#8211; 63 ko Preuve de r\u00e9clamation &#8211; 173 ko Lettre d&rsquo;instruction &#8211; dat\u00e9 10 octobre 2018 &#8211; 88 ko Ordonnance de proc\u00e9dure de [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","insolvency-initial":[346,360],"class_list":["post-6844","insolvencies","type-insolvencies","status-publish","hentry","insolvency-initial-a","insolvency-initial-o"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aralez Pharmaceuticals<\/title>\n<meta name=\"description\" content=\"Aralez Pharmaceuticals - Dossier de restructuration\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aralez Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"Aralez Pharmaceuticals - Dossier de restructuration\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Richter\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Richtercanada\/\" \/>\n<meta property=\"article:modified_time\" content=\"2019-05-31T14:22:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/08\/share-og.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1008\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@richtercanada\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/\",\"url\":\"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/\",\"name\":\"Aralez Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/www.www.richter.ca\/#website\"},\"datePublished\":\"2018-12-13T22:49:40+00:00\",\"dateModified\":\"2019-05-31T14:22:41+00:00\",\"description\":\"Aralez Pharmaceuticals - Dossier de restructuration\",\"breadcrumb\":{\"@id\":\"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Richter\",\"item\":\"https:\/\/www.richter.ca\/fr\/accueil\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insolvency cases\",\"item\":\"https:\/\/www.www.richter.ca\/insolvencycase\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Aralez Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.www.richter.ca\/#website\",\"url\":\"https:\/\/www.www.richter.ca\/\",\"name\":\"Richter\",\"description\":\"Un site utilisant WordPress\",\"publisher\":{\"@id\":\"https:\/\/www.www.richter.ca\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.www.richter.ca\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.www.richter.ca\/#organization\",\"name\":\"Richter\",\"url\":\"https:\/\/www.www.richter.ca\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.www.richter.ca\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.richter.ca\/wp-content\/uploads\/2018\/08\/logo.png\",\"contentUrl\":\"https:\/\/www.richter.ca\/wp-content\/uploads\/2018\/08\/logo.png\",\"width\":128,\"height\":24,\"caption\":\"Richter\"},\"image\":{\"@id\":\"https:\/\/www.www.richter.ca\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Richtercanada\/\",\"https:\/\/x.com\/richtercanada\",\"https:\/\/www.instagram.com\/richtercanada\",\"https:\/\/www.linkedin.com\/company\/richter\/?trk=hb_tab_compy_id_255303\"],\"address\":[{\"@type\":\"PostalAddress\",\"addressLocality\":\"Montreal, QC, Canada\",\"postalCode\":\"H3A 0G6\",\"streetAddress\":\"1981 McGill College, #1100 The Richter Tower\"},{\"@type\":\"PostalAddress\",\"addressLocality\":\"Toronto, ON, Canada\",\"postalCode\":\"M5J 2T3\",\"streetAddress\":\"181 Bay St. #3510 Bay Wellington Tower\"},{\"@type\":\"PostalAddress\",\"addressLocality\":\"Chicago, IL, United States\",\"postalCode\":\"60606\",\"streetAddress\":\"200 South Wacker, #3100\"}],\"contactPoint\":[{\"@type\":\"ContactPoint\",\"telephone\":\"+1-514-934-3400\",\"contactType\":\"Montreal office\"},{\"@type\":\"ContactPoint\",\"telephone\":\"+1-416-488-2345\",\"contactType\":\"Toronto office\"},{\"@type\":\"ContactPoint\",\"telephone\":\"+1-312-828-0800\",\"contactType\":\"Chicago office\"}]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aralez Pharmaceuticals","description":"Aralez Pharmaceuticals - Dossier de restructuration","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Aralez Pharmaceuticals","og_description":"Aralez Pharmaceuticals - Dossier de restructuration","og_url":"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/","og_site_name":"Richter","article_publisher":"https:\/\/www.facebook.com\/Richtercanada\/","article_modified_time":"2019-05-31T14:22:41+00:00","og_image":[{"width":1920,"height":1008,"url":"https:\/\/richterca.tor1.digitaloceanspaces.com\/wp-content\/uploads\/2018\/08\/share-og.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@richtercanada","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/","url":"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/","name":"Aralez Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.www.richter.ca\/#website"},"datePublished":"2018-12-13T22:49:40+00:00","dateModified":"2019-05-31T14:22:41+00:00","description":"Aralez Pharmaceuticals - Dossier de restructuration","breadcrumb":{"@id":"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.www.richter.ca\/fr\/insolvencycase\/aralez-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Richter","item":"https:\/\/www.richter.ca\/fr\/accueil\/"},{"@type":"ListItem","position":2,"name":"Insolvency cases","item":"https:\/\/www.www.richter.ca\/insolvencycase\/"},{"@type":"ListItem","position":3,"name":"Aralez Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/www.www.richter.ca\/#website","url":"https:\/\/www.www.richter.ca\/","name":"Richter","description":"Un site utilisant WordPress","publisher":{"@id":"https:\/\/www.www.richter.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.www.richter.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.www.richter.ca\/#organization","name":"Richter","url":"https:\/\/www.www.richter.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.www.richter.ca\/#\/schema\/logo\/image\/","url":"https:\/\/www.richter.ca\/wp-content\/uploads\/2018\/08\/logo.png","contentUrl":"https:\/\/www.richter.ca\/wp-content\/uploads\/2018\/08\/logo.png","width":128,"height":24,"caption":"Richter"},"image":{"@id":"https:\/\/www.www.richter.ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Richtercanada\/","https:\/\/x.com\/richtercanada","https:\/\/www.instagram.com\/richtercanada","https:\/\/www.linkedin.com\/company\/richter\/?trk=hb_tab_compy_id_255303"],"address":[{"@type":"PostalAddress","addressLocality":"Montreal, QC, Canada","postalCode":"H3A 0G6","streetAddress":"1981 McGill College, #1100 The Richter Tower"},{"@type":"PostalAddress","addressLocality":"Toronto, ON, Canada","postalCode":"M5J 2T3","streetAddress":"181 Bay St. #3510 Bay Wellington Tower"},{"@type":"PostalAddress","addressLocality":"Chicago, IL, United States","postalCode":"60606","streetAddress":"200 South Wacker, #3100"}],"contactPoint":[{"@type":"ContactPoint","telephone":"+1-514-934-3400","contactType":"Montreal office"},{"@type":"ContactPoint","telephone":"+1-416-488-2345","contactType":"Toronto office"},{"@type":"ContactPoint","telephone":"+1-312-828-0800","contactType":"Chicago office"}]}]}},"_links":{"self":[{"href":"https:\/\/www.richter.ca\/fr\/wp-json\/wp\/v2\/insolvencies\/6844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.richter.ca\/fr\/wp-json\/wp\/v2\/insolvencies"}],"about":[{"href":"https:\/\/www.richter.ca\/fr\/wp-json\/wp\/v2\/types\/insolvencies"}],"wp:attachment":[{"href":"https:\/\/www.richter.ca\/fr\/wp-json\/wp\/v2\/media?parent=6844"}],"wp:term":[{"taxonomy":"insolvency-initial","embeddable":true,"href":"https:\/\/www.richter.ca\/fr\/wp-json\/wp\/v2\/insolvency-initial?post=6844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}